By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > CNS stimulants > Dexmethylphenidate and serdexmethylphenidate > Dexmethylphenidate and serdexmethylphenidate Pregnancy and Breastfeeding Warnings
CNS stimulants

Dexmethylphenidate / serdexmethylphenidate Pregnancy and Breastfeeding Warnings

Contents
Dexmethylphenidate and serdexmethylphenidate Pregnancy Warnings Dexmethylphenidate and serdexmethylphenidate Breastfeeding Warnings

Dexmethylphenidate and serdexmethylphenidate Pregnancy Warnings

Animal studies have shown delayed fetal skeletal ossification at dexmethylphenidate doses up to 3 times the maximum recommended human dose (MRHD) in rats. At this same dose, decreased weight was observed in male pups in pre- and post-natal development studies. In an embryo-fetal development study with serdexmethylphenidate in rabbits, developmental effects were not observed at doses up to approximately 49 times the MRHD. There is concern that CNS stimulants may cause vasoconstriction and decrease placental perfusion. Fetal and/or neonatal adverse reactions have not been reported with therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

Benefit should outweigh risk

US FDA pregnancy category: Not assigned

Risk Summary: There are no data available on use of this drug in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes; published studies and postmarketing reports on methylphenidate use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes, although there may be risks to the fetus associated with the use of CNS stimulants during pregnancy.

Comments:
-There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to medications used for ADHD (attention deficit hyperactivity disorder); healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychostimulants at 1-866-961-2388.

See references

Dexmethylphenidate and serdexmethylphenidate Breastfeeding Warnings

Benefit should outweigh risk

Excreted into human milk: Unknown (serdexmethylphenidate/dexmethylphenidate) Yes (methylphenidate)

Comments:
-Breastfed infants should be monitored for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain.
-Long term neurodevelopmental effects on infants from CNS stimulant exposure are not known.

Serdexmethylphenidate is a prodrug of dexmethylphenidate and dexmethylphenidate is the more pharmacologically active d-enantiomer of racemic methylphenidate. There is no information on use of this coformulated drug during lactation. In a limited number of women prescribed methylphenidate for medical indications, the amount of methylphenidate excreted in milk has been found to be low and not detectable in infant serum. It is estimated that a fully breastfed infant would receive a relative dose of 0.2% to 0.7% of the maternal weight adjusted dose. In a study of 7 infants whose mothers received either methylphenidate (average 52 mg/day) or dextroamphetamine (average dose 25 mg/day), no drug-related adverse reactions were reported and normal development for age was observed (average age 4.4 months). Long-term neurodevelopmental effects on infants from stimulant exposure are unknown.

See references

Share this Article
Latest News
Medical News

Obesity, unhealthy lifestyles may cause heart to age by 5–45 years

May 08, 2025
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Heart disease: Just 3 minutes of 'incidental activity' may lower...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by